Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zhengye Biotechnology HoldingZYBT +0.26%20 Gross Margin % is 8.30% as of Dec. 2025, which is 85% below its 10-year median of 55.52. GuruFocus rates ZYBT with a GF Score™ of 20/100. The stock has 5 warning signs investors should review. Among 938 Drug Manufacturers companies, Zhengye Biotechnology Holding ranks worse than 90.83% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Zhengye Biotechnology Holding had a gross margin of 8.30% for the quarter that ended in Dec. 2025 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Zhengye Biotechnology Holding Gross Margin % Related Terms
Zhengye Biotechnology Holding Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ZYBT vs TLPH, CPHI, CPIX: Gross Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Zhengye Biotechnology Holding's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhengye Biotechnology Holding Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Zhengye Biotechnology Holding's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Zhengye Biotechnology Holding's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Zhengye Biotechnology Holding (ZYBT) has a Gross Margin % of 8.30% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Zhengye Biotechnology Holding and its competitors. This is 85% below median its historical median of 55.52. Over the past decade, Zhengye Biotechnology Holding's Gross Margin % has ranged from 20.41 to 58.58. According to the industry distribution chart, Zhengye Biotechnology Holding ranks #852 out of 938 companies in the Drug Manufacturers industry, placing it in the top 90.8%.
Is Zhengye Biotechnology Holding's Gross Margin % too high?
Zhengye Biotechnology Holding's current Gross Margin % of 8.30% is 85% below median its 10-year median of 55.52. Over the past 10 years, this metric has ranged from a low of 20.41 to a high of 58.58. The Drug Manufacturers industry median Gross Margin % is 48.51. Zhengye Biotechnology Holding's value of 8.30% is 82.9% below this industry median. Based on the distribution chart, Zhengye Biotechnology Holding ranks #852 out of 938 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Zhengye Biotechnology Holding has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Zhengye Biotechnology Holding's Gross Margin % compare to TLPH and CPHI?
According to the Drug Manufacturers industry distribution chart, Zhengye Biotechnology Holding ranks #852 out of 938 companies for Gross Margin %. This places Zhengye Biotechnology Holding in the lower half of its industry. The industry median Gross Margin % is 48.51. Zhengye Biotechnology Holding's value of 8.30% is 82.9% below this benchmark. Historically, Zhengye Biotechnology Holding's own Gross Margin % has ranged from 20.41 to 58.58 over the past decade. While the company's 10-year median is 55.52 vs. the industry median of 48.51, Zhengye Biotechnology Holding has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.51, based on 938 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zhengye Biotechnology Holding's current Gross Margin % of 8.30% is 82.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Zhengye Biotechnology Holding and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zhengye Biotechnology Holding's current Gross Margin % is 8.30%, which is 85% below median its own 10-year median of 55.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhengye Biotechnology Holding stock overvalued right now?
Zhengye Biotechnology Holding (ZYBT) has a current Gross Margin % of 8.30%. The current Gross Margin % is 8.30%, which is 85% below median its 10-year median of 55.52 and 82.9% below the Drug Manufacturers industry median of 48.51. Zhengye Biotechnology Holding's overall GF Score™ is 20/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Zhengye Biotechnology Holding (ZYBT), the current Gross Margin % is 8.30% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Zhengye Biotechnology Holding Ltd is engaged in research, development, manufacturing, and sales of veterinary vaccines, with an emphasis on vaccines for livestock. It has a diverse range of vaccines, including vaccines for swine, cattle, goats, waterfowl, sheep, poultry, and pets, available in various provincial regions across China and are exported overseas to Vietnam, Pakistan, and Egypt. The company generates maximum revenue from the sale of swine vaccines, followed by poultry and other vaccines.
20GF Score
Get the complete analysis for ZYBT
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZYBT has been successfully added to your 
